SynopsisAmphetamine (alpha-methylphenethylamine) is a central nervous system (CNS) stimulant that affects the nervous system of the body targeting brain chemicals for hyperactivity and impulse control. The global Amphetamine Drug market was valued at US$ 341 mil.....
SynopsisKEYTRUDA® (pembrolizumab) works as an immunotherapy to help fight certain cancers. The global Keytruda market was valued at US$ 20940 million in 2023 and is anticipated to reach US$ 46510 million by 2030, witnessing a CAGR of 10.5% during the forecast pe.....
SynopsisOPDIVO® (nivolumab) is a prescription medication that treats certain types of cancer. The global OPDIVO market was valued at US$ 9567 million in 2023 and is anticipated to reach US$ 15620 million by 2030, witnessing a CAGR of 6.8% during the forecast per.....
SynopsisIMFINZI® (durvalumab) is an immunotherapy used to treat patients with urothelial carcinoma, a type of bladder cancer The global Imfinzi market was valued at US$ 2784 million in 2023 and is anticipated to reach US$ 5734.7 million by 2030, witnessing a CAG.....
SynopsisOPDIVO® (nivolumab) is a prescription medication that treats certain types of cancer. The global Nivolumab Drugs market was valued at US$ 9567 million in 2023 and is anticipated to reach US$ 15620 million by 2030, witnessing a CAGR of 6.8% during the for.....
SynopsisPD-L1 inhibitors are a group of checkpoint inhibitor anticancer drugs The global PD-L1 Inhibitors market was valued at US$ 8139 million in 2023 and is anticipated to reach US$ 11170 million by 2030, witnessing a CAGR of 4.7% during the forecast period 20.....
SynopsisAn implanted port (also known as a “port”) is like an artificial vein. It will make it easier for doctors and nurses to access the blood vessels for medications and tests. The global Totally Implantable Access Port market was valued at US$ 480 million in.....
SynopsisCell Freezing Medium is a complete cell freezing media for mammalian cell cultures. The global GMP Grade Cell Freezing Media market was valued at US$ 386 million in 2023 and is anticipated to reach US$ 758.2 million by 2030, witnessing a CAGR of 10.0% du.....
SynopsisZEPOSIA (ozanimod) is a new oral treatment for adults with relapsing forms of MS The global Zeposia market was valued at US$ 250 million in 2023 and is anticipated to reach US$ 1239.7 million by 2030, witnessing a CAGR of 18.4% during the forecast period.....
SynopsisSiponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS). It is intended for once-daily oral administration. The global Siponimod market was valued at US.....
